Introduction
This article reviews recent trends in heart and lung transplantation in the United States. The data reported here are drawn from the 2007 OPTN/SRTR Annual Report, and cover all aspects of thoracic organ transplantation in the last decade. Two recent changes in the allocation systems for these two organs-the Lung Allocation Score system, introduced in May 2005, and the increased geographic sharing of hearts, introduced in July 2006-seem to be having noticeable effects on transplantation trends. Both systems were introduced in order to save lives. The data available for evaluating the beneficial effects of these allocation changes are not yet quite mature, but interesting trends are becoming apparent, as described throughout this article. Critics have challenged some of the early data interpretation of these changes, as preliminary analyses (like the statistical models behind the changes themselves) were based on 1-year risk of patient death, rather than longer-term risk. Five-year survival rates were not used to develop these allocation systems, but they will be valuable when they become available. Revisions in both allocation schemes are ongoing, as factors are identified that may enhance the systems' ability to make the best use of this scarce resource.
Heart
Heart waiting list characteristics The characteristics of heart transplant candidates are derived from potential transplant recipients actively awaiting heart transplantation at the end of each calendar year from 1997 to 2006. Overall, the total number of active candidates declined by 45% over the decade, dropping from 2414 patients in 1997 to 1327 patients in 2006.
The percentage of patients actively awaiting heart transplantation with blood type O increased by approximately 9% over the last 10 years. Other characteristics of heart transplant candidates, including country of residence, history of previous transplant with any organ or history of previous heart or lung transplant, remained relatively unchanged (≤2% change) from 1997 to 2006.
Patients awaiting heart transplantation are assigned a level of urgency based on medical condition and include, from most to least urgent: Status 1A, Status 1B and Status 2. A Status 1A candidate has either mechanical circulatory support for acute hemodynamic decompensation, mechanical circulatory support with objective medical evidence of device-related complications, continuous mechanical ventilation or intra-aortic balloon pump, or continuous infusion of intravenous inotropes along with continuous monitoring of left ventricular filling pressures. Additionally, a patient may be listed as Status 1A in the absence of these conditions if the transplant physician submits an application for Status 1A to the Regional Review Board and the application is approved. patients listed as Status 2, only 6%, 8% and 11% received a heart transplant by 30, 60 and 90 days, respectively.
Deaths on the heart waiting list
The overall death rates among patients awaiting heart transplantation have declined over the last 10 years, from 227 per 1000 patient-years at risk in 1997 to 152 per 1000 patient-years at risk in 2006 ( Figure 2 ). This trend was clearly evident regardless of ethnicity, sex, blood type (except blood group AB), age (except for patients <1 year old) and diagnosis (except for retransplant/graft failure/unknown). Death rates on the heart waiting list decreased sharply among Status 1A candidates, from 2087 deaths per 1000 patient-years at risk in 2000 to 1457 deaths per 1000 patient-years at risk in 2006 ( Figure 3 ). Death rates among Status 1B and Status 2 patients declined as well, though less sharply and with more year-to-year variability ( Figure 3 ). The increasing prevalence of ventricular assist device (VAD) placement may have contributed to the declining death rates, particularly among Status 1A patients. 
Heart and Lung Transplantation in the United States, 1997-2006
Heart transplant recipient characteristics The overall number of heart transplants performed has varied by 14% over the past decade, from a high of 2348 in 1998 to a low of 2015 in 2004. After reaching a 10-year low in 2004, the number of transplants increased slightly in each of the past 2 years. There was also a 14% decrease in the rate of heart transplants per million US residents over the last 10 years, though this trend appears to have leveled off over the last few years (Figure 4) . Among patients transplanted, there has been an 18% decrease in the 50-64 age group, a 19% reduction in the number of white recipients and a 24% reduction in the number of patients transplanted with a diagnosis of coronary artery disease. As with changes in waiting list characteristics, these changes have resulted in greater percentages of patients receiving transplants among younger age groups, nonwhites and candidates with a diagnosis other than coronary artery disease. Other important trends have included a 51% reduction in the number of patients hospitalized in an intensive care unit before heart transplantation and a reciprocal increase in the number of patients hospitalized outside an intensive care unit or not hospitalized at all before heart transplantation. There has also been a 17% reduction in the number of patients on life support (extracorporeal membrane oxygenation, intra-aortic balloon pump, prostaglandins, intravenous inotropes, inhaled nitric oxide, ventilator) at the time of heart transplantation over the past decade. There have been no significant changes in the characteristics of heart transplant recipients with respect to sex (approximately 75% of heart recipients are male), recipient blood type, previous transplant with any organ, previous heart or heart-lung transplant and recipient residency.
The distribution of patients among the different status groups on the waiting list at the time of heart transplantation changed little between the inception of the new classification system in 1999 and 2005. At that time patients at Status 1A, 1B and 2 at the time of transplan- 
Immunosuppression therapy for heart transplantation
The immunosuppression regimen for heart transplant recipients has continued to evolve over the past decade. mycophenolate mofetil/myocophenolic acid and steroids (49% of transplant recipients)-and, to a lesser extent (29% of transplant recipients), cyclosporine, mycophenolate mofetil/myocophenolic acid and steroids. At 1 year following transplantation, triple drug therapy with a calcineurin antagonist (principally tacrolimus), mycophenolate mofetil/myocophenolic acid and steroid therapy remains the predominant treatment regimen. However, since 1997 there has been a small (approximately 15% of patients) but important trend toward steroid-free drug regimens by 1 year following transplantation. Heart transplant recipients discharged on tacrolimus and mycophenolate mofetil/myocophenolic acid, with or without steroid therapy, have the greatest likelihood of remaining on this drug regimen, compared to all other drug combinations at 3 years following transplantation. A notable trend is the declining number of recipients who needed treatment for rejection episodes during the first year following transplantation (25% in 2005 compared to 36% in 1996). An overwhelming majority of patients were treated with steroid therapy while approximately 18% were treated with some form of antibody therapy. The decline probably reflects the improved efficacy of the newer immunosuppression medications, but also may result from incremental improvements in the overall care of donors and recipients. The incidence of infection and malignancy require further analysis to identify meaningful trends.
Heart transplant outcomes
Deaths in the first year after heart transplantation have steadily decreased from 171 deaths per 1000 patient-years at risk in 1997 to 132 deaths per 1000 patient-years at risk in 2003 (Figure 6 ). There has been a slight increase in the incidence of death during the last 2 years, to 142 deaths per 1000 patient-years at risk. Adjusted to the characteristics of the 1996 heart transplant population (age, sex, race and diagnosis), patient survival at 3 months and 1 year improved from 89.7 ± 0.6% and 85.2 ± 0.7%, respectively, in 1996, to 92.1 ± 0.6% and 87. for coronary artery disease, 112 for cardiomyopathy and 105 for valvular heart disease.
Heart allocation policy changes
In July 2006, the OPTN Thoracic Organ Transplantation Committee implemented an allocation policy change moving Zone A 1A and 1B patients ahead of local Status 2 patients (1). It is predicted that the policy change will result in fewer deaths on the waiting list and overall. However, very little follow-up has yet been accrued, even for those patients transplanted earliest during the era affected by the policy change. While some impact from the policy change may be reflected in the trends described above, it is expected that a more comprehensive review of the new policy's effect can be made in future reports, after sufficient numbers of patients have received transplants under the new system and adequate follow-up has been accrued. 
Lung
The lung transplantation section of this article is organized differently than the heart section because policy changes following the institution of the Lung Allocation Score (LAS) system are most logically reviewed in terms of deaths on the waiting list and following transplantation. Rather than a discussion of waiting list characteristics and outcomes followed by a discussion of transplant recipient characteristics and outcomes, the discussion of waiting list and transplant characteristics and outcomes is combined. (Here, and in subanalyses below, the total number of deaths includes all deaths after transplant during the year, regardless of when the transplant occurred.) Taken in combination, the net gain was 5.5 deaths prevented per 1000 patient-years at risk. It remains to be seen whether this pattern will continue and how long-term death rates may alter the picture of net gain. The increases in posttransplant death rates between 2004 and 2005 can likely attributed to sicker patients being selected for transplant during these years. It should also be noted that the total number of deaths presented here do not account for patients who may have been removed from the list because they were too ill to receive a transplant and who subsequently died. Since May 2005 more acutely ill patients have been listed for transplantation, and it is probable that some are indeed removed from the waiting list and die shortly thereafter. Consequently, a composite risk of death for all patients may not be completely captured by the data presented here.
Lung: Overview
Once adjusted for age, race, sex and diagnostic characteristics of the 1996 transplant cohort, posttransplant patient survival rates were comparable to those seen in previous years, 92% at 3 months and 84% at 1 year ( Figure 15 ). (It is important to note that disease severity was not adjusted for in these comparisons, as much more information is available now than was available in 1996.) Three-year survival rates for these patients will not be available for another 2 years.
Lung: Breakdown by age
The age distribution of active patients on the lung waiting list has changed over the past decade (Figure 16 ). , total deaths among patients aged 11-17 years dropped from 38 to 29, a 24% decrease. The other age groups experienced smaller changes in total deaths. Total deaths among patients aged less than 11 years remained constant, among patients aged 18-34 years dropped by 5%, among patients aged 35-49 years rose by 5%, among patients aged 50-64 years dropped by 4% and among patients 65 years and older rose by 6%.
Lung: Breakdown by diagnosis groups
The diagnosis distribution of wait-listed patients changed noticeably between 2004 and 2006. The most pronounced shifts were seen in the percentage of patients with idiopathic pulmonary fibrosis (IPF), which decreased from 18% to 14% of listed patients, and the percentage of patients with chronic obstructive pulmonary disease (COPD), which increased from 31% to 36% of listed patients (Figure 18 ). This change reflects, in part, a relative increase in the number of IPF patients transplanted due to higher LAS than that of COPD patients. Despite this shift, emphysema and COPD remain the most common diagnoses leading to transplantation (Figure 19 of when the transplant occurred), however, decreased for all of the diagnosis groups. In 2005, total deaths among PPH patients dropped from 57 to 53 (7%), among CF patients dropped from 196 to 166 (15%), among IPF patients dropped from 280 to 258 (8%), and among emphysema/COPD patients dropped from 389 to 370 (5%). , 128 patients with a previous lung or heart-lung transplant were retransplanted with a deceased donor lung, more retransplants than were performed in the previous 4 years combined. In 2005, 305 deaths per 1000 patient-years were observed among patients with any previous transplant, a 57% higher death rate than seen for recipients without previous transplants. These trends of increasing posttransplant mortality for patients rejoining the lung waiting list must be monitored closely. Further analysis of the risk-benefit profile for retransplantation and appropriate policy changes in lung allocation scoring should be considered as results emerge.
The number of bilateral lung transplants has more than doubled over the decade, rising from 432 (48% of deceased donor lung transplants) in 1997 to 897 (64% of transplants) in 2006 (Figure 22 ). In 2005, first-year posttransplant death rates were 7% lower for double lung recipients than for single lung recipients, although this comparison does not adjust for multivariate factors such as diagnosis and age (Figure 23 ). Because the survival advantage conferred by a double lung transplant is still unclear, further analysis is needed, including the impact on organ utilization of more double lung transplants being performed. Appropriate use of marginal donor lungs typically mandates double lung transplantation. Consequently, the liberal performance of double lung transplantation may not hinder aggressive and appropriate use of available donor lungs. 
Lung: Breakdown by ethnicity
There has been minimal variation in ethnic makeup of the active waiting list over the past 10 years. Hispanic patients had much higher waiting list death rates than whites, African Americans or Asians in 2006. This higher death rate cannot be explained by a difference in proportion between candidates and recipients, as both groups were 5% Hispanic in 2006. The median time-to-transplant was longer for Hispanic patients (192 days) than for whites (128 days) and African Americans (132 days), but not Asians (262 days). Death rates in the first year after lung transplant were within random variation for Hispanic, white and AfricanAmerican patients, although the death rate was lowest for African Americans. The 2005 death rate for Asian patients was particularly poor (517 deaths per 1000 patient-years), but this rate is based on very small numbers. White patients continue to make up the majority of patients waiting (86%) and being transplanted (85%).
Immunosuppression therapy after lung transplantation Induction therapy was used for 57% of all lung transplants performed in 2006, up from only 22% of lung transplants in 1997. The induction therapies used most commonly in 2006 were basiliximab (Simulect) (24%) and daclizumab (Zenapax) (16%). In 1997, antithymocyte globulin induction therapy (was used for 20% of transplants and was by far the most common therapy. In 2006, baseline therapy prior to discharge included corticosteroids (97%), tacrolimus (Prograf ® , Astellas Pharma US, Deerfield, IL) (83%), and an antimetabolite-either azathioprine (Imuran, GlaxoWellcome, New Zealand) (39%) or mycophenolate mofetil (Cellcept, Roche, Nutley, NJ) (52%)). Calcineurin inhibitor use has changed dramatically-from the predominant use of cyclosporine (Neoral or Sandimmune, Novartis, East Hanover, NJ) (75%) in 1997 to tacrolimus (83%) in 2006. In 2005, maintenance immunosuppression administered for the first year following transplantation was essentially the same as immunosuppression before discharge, except that the use of tacrolimus increased from 76% to 86% and the use of sirolimus increased from 1% to 8% of lung transplants. The immunosuppressive agents most commonly used to treat acute rejection within the first year after transplant were corticosteroids, used in 95% of acute rejection cases.
Center and donor lung transplant outcomes
Centers with a volume greater than 21 transplants per year had higher 5-year unadjusted graft and patient survival rates (53% and 56%, respectively) than did lower-volume centers (39-48% and 45-51%, respectively). Recipients of lungs from donors aged 18-34 years had the best unadjusted 5-year patient survival rates (56%), aside from recipients from donors <1 (71%, based on small numbers). Recipients of lungs from donors aged 65 years and above had the lowest patient survival (47%).
Heart-Lung
After falling steadily from 164 candidates at the end of 1997 to only 45 at the end of 2005, the number of patients on the active waiting list for a heart-lung transplant increased slightly in 2006, to 53 patients. These numbers are very small compared to the 1327 active heart waiting list patients and 1032 active lung waiting list patients. The death rate on the waiting list in 2006 (143 per 1000 patient-years at risk) was significantly lower than it was in 1997 (284).
Only 31 heart-lung transplants were performed in 2006, down from a high of 62 in 1997. Nearly half the heartlung recipients were aged 35-49 years, and the most common diagnoses were PPH and congenital heart disease. There were 54 transplant centers that performed heart-lung transplants at some point between 1997 and 2006, but only 15 performed a combined transplant
